न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - sodium valproate 200mg; sodium valproate 200mg; sodium valproate 200mg - modified release tablet - 200 mg - active: sodium valproate 200mg excipient: calcium silicate citric acid diethyl phthalate hypromellose macrogol 6000 magnesium stearate opaspray violet k-1-4613 polyvinylacetate phthalate povidone purified talc stearic acid active: sodium valproate 200mg excipient: calcium silicate citric acid diethyl phthalate hypromellose macrogol 6000 magnesium stearate opaspray polyvinylacetate phthalate povidone purified talc stearic acid active: sodium valproate 200mg excipient: calcium silicate magnesium stearate povidone purified talc violet enteric coat excipient blend violet sub-coat excipient blend - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy.

न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - sodium valproate 500mg; sodium valproate 500mg; sodium valproate 500mg - modified release tablet - 500 mg - active: sodium valproate 500mg excipient: calcium silicate citric acid diethyl phthalate hypromellose macrogol 6000 magnesium stearate opaspray polyvinylacetate phthalate povidone purified talc stearic acid active: sodium valproate 500mg excipient: calcium silicate citric acid diethyl phthalate hypromellose macrogol 6000 magnesium stearate opaspray polyvinylacetate phthalate povidone purified talc stearic acid active: sodium valproate 500mg excipient: calcium silicate magnesium stearate povidone purified talc violet enteric coat excipient blend violet sub-coat excipient blend - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy.

न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - sodium valproate 400mg - powder for injection with diluent - 100 mg/ml - active: sodium valproate 400mg excipient: water for injection - epilim iv: the treatment of patients with epilepsy or bipolar disorder, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.

न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - sodium valproate 40 mg/ml;   - oral solution - 200 mg/5ml - active: sodium valproate 40 mg/ml   excipient: cherry flavour 17.40.0740 citric acid hyetellose ponceau 4r purified water saccharin sodium sodium methyl hydroxybenzoate sodium propyl hydroxybenzoate sorbitol - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy.

न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - rasburicase 1.5mg - powder for infusion - 1.5 mg - active: rasburicase 1.5mg excipient: alanine dibasic sodium phosphate dihydrate dibasic sodium phosphate dodecahydrate mannitol monobasic sodium phosphate dihydrate poloxamer 188 water for injection - the treatment and prophylaxis of acute hyperuricaemia, in patients with haematological malignancy at risk of a rapid tumour lysis.

न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - clobazam 10mg - tablet - 10 mg - active: clobazam 10mg excipient: colloidal silicon dioxide lactose monohydrate magnesium stearate maize starch purified talc - adjunctive therapy in partial or generalised epilepsy and monotherapy in certain forms of epilepsy such as lennox-gastaut and catamenial epilepsy.

न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - amiloride hydrochloride dihydrate 5mg;  ;  ; furosemide 40mg - tablet - 40mg/5mg - active: amiloride hydrochloride dihydrate 5mg     furosemide 40mg excipient: colloidal silicon dioxide lactose monohydrate magnesium stearate maize starch microcrystalline cellulose purified talc sodium starch glycolate sunset yellow fcf - frumil is indicated for the treatment of cardiac failure, in patients who require diuretics plus potassium supplements, or potassium sparing diuretics.

न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - amphotericin b 10mg (overage of 20% (12mg)) - lozenge - 10 mg - active: amphotericin b 10mg (overage of 20% (12mg)) excipient: acacia curacao flavour 50397 ap0500 mannitol orange flavour orange flavour 051226t polyvinyl alcohol purified talc saccharin sodium sodium cyclamate stearic acid - for the treatment of candidal lesions (thrush) of the oral and perioral areas.

न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - polio virus type 1 29 dagu (mahoney by parallel line method (equiv to 40 dagu by sigmoid method)); polio virus type 2 7 dagu (mef1 by parallel line method (equiv to 8 dagu by sigmoid method)); polio virus type 3 26 dagu (saukett by parallel line method (equiv to 32 dagu by sigmoid method)) - suspension for injection - active: polio virus type 1 29 dagu (mahoney by parallel line method (equiv to 40 dagu by sigmoid method)) polio virus type 2 7 dagu (mef1 by parallel line method (equiv to 8 dagu by sigmoid method)) polio virus type 3 26 dagu (saukett by parallel line method (equiv to 32 dagu by sigmoid method)) excipient: formaldehyde phenoxyethanol polysorbate 80 water for injection - ipol is indicated for active immunisation of infants, children and adults for the prevention of poliomyelitis. recommendations for the use of live and inactivated poliovirus vaccines are described in the national immunisation guidelines. 1. general recommendations. it is recommended that all infants, unimmunised children and adolescents not previously immunised be vaccinated routinely against paralytic poliomyelitis. ipol should be offered to patients who have refused opv, or in whom opv is contraindicated. 2. ipol is also indicated for: · the primary vaccination of immunocompromised individuals of all ages (see precautions), and household contacts of such individuals (when vaccination is indicated) · unvaccinated or inadequately vaccinated (*) adults, particularly if at increased risk of exposure to live poliovirus, including: · travellers to areas or countries where poliomyelitis is epidemic or endemic; · laboratory workers handling specimens which may contain polioviruses; · health care workers in close contact with patients who may be excreting polioviruses. (*) such as those who had not completed a primary series of vaccination or not received a booster dose since infancy.

न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - furosemide 10 mg/ml; furosemide 10 mg/ml - oral solution - 10 mg/ml - active: furosemide 10 mg/ml excipient: butylated hydroxyanisole butylated hydroxytoluene ethanol glycerol methyl hydroxybenzoate orange flavour 987431 polysorbate 80 potassium sorbate quinoline yellow sodium hydroxide sorbitol water active: furosemide 10 mg/ml excipient: ethanol glycerol methyl hydroxybenzoate orange flavour propyl hydroxybenzoate purified water quinoline yellow sodium hydroxide sorbitol sunset yellow fcf - oedema lasix is indicated in adults, infants and children for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver and renal disease including the nephrotic syndrome. lasix is particularly useful when an agent with greater diuretic potential than that of those commonly employed is desired. parenteral therapy should be reserved for patients unable to take oral medication or for patients in emergency clinical situations. lasix injection is also indicated as adjunctive therapy in acute pulmonary oedema and cerebral oedema where intense and rapid onset of diuresis is desired. if gastrointestinal absorption is impaired or oral medication is not practical for any reason, lasix is indicated by the intravenous route. parenteral use should be replaced with oral lasix as soon as practical.